Atala Financial’s AbbVie ABBV Stock Holding History

Atala Financial’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-321	Closed	-$67.3K	–	131
2025 Q1	$67.3K	Hold	321	–	–	0.05%	163
2024 Q4	$57K	Buy	+321	New	+$59K	0.04%	177

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Atala Financial's ABBV Position: Q2 2025 in Review

Atala Financial sold out of AbbVie (ABBV) in Q2 2025, closing a stake of 321 shares — an estimated $67.3K sold.

Atala Financial first reported a position in ABBV in Q4 2024 and held it in 2 quarters. The position peaked at $67.3K in Q1 2025. 3,780 funds tracked by Wall St. Rank hold ABBV as of Q2 2025.

Atala Financial reported no remaining AbbVie position as of Q2 2025 after selling out during the quarter.
Atala Financial sold 321 AbbVie shares in Q2 2025, an estimated $67.3K.
Atala Financial first reported a position in AbbVie in Q4 2024 and held it in 2 quarters.
Atala Financial's AbbVie position peaked at $67.3K in Q1 2025.
3,780 funds tracked by Wall St. Rank held AbbVie as of Q2 2025.

Based on Atala Financial's 13F filing for Q2 2025, filed 7 Aug 2025.